MedPath

Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies

Completed
Conditions
Multiple Sclerosis
Registration Number
NCT01020370
Lead Sponsor
Wayne State University
Brief Summary

The primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies using conventional and non-conventional MRI sequences.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Participating in either the CARE MS I or CARE MS II studies
Exclusion Criteria
  • Not a participant in the CARE MS I or CARE MS II studies

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies
Secondary Outcome Measures
NameTimeMethod
Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes
© Copyright 2025. All Rights Reserved by MedPath